课题基金 / 基金详情

Ontogeny & Maintenance of Virus Specific T Cells

Ontogeny & Maintenance of Virus Specific T Cells
个体发育
批准号:
6632320
负责人:
JOHN Lewis SULLIVAN
金额:
$103.66万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-05-24 至 2006-04-30

项目摘要

项目成果

JOHN Lewis SULLIVAN的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The urgency and importance of an effective vaccine for HIV is widely appreciated yet many additional viral vaccines are in need of development or improvement; herpesviruses; respiratory; enteric viruses; Hemorrhagic fevers; to name only a few. Remarkable advances in molecular biology and cellular immunology have set the stage for a new era of vaccine development. The goals of this program project are these: 1) To examine the induction, evolution, and stability of virus-specific T lymphocyte responses to a persistent virus infection (Epstein-Barr Virus) and to a non-persistent virus infection without repeated antigenic exposure (vaccinia); 2) To study the effects of unrelated antigens on the evolution of virus-specific memory T lymphocyte populations; 3) To examine the goals outlined in 1 and 2 across the age spectrum; The Program Project format affords the promise of generating a comprehensive understanding of virus-specific memory T lymphocyte responses in humans than could be achieved by investigators working in isolation. Project #1 will extend our quantitative and qualitative analyses of the EBV epitope-specific CTL response and test the hypothesis that the nature of this response will be different in adults, who often develop severe symptoms, and children, who are often asymptomatic. Project #2 will test the hypothesis that crossreactive T cell responses between different viruses are common during viral infections and that memory T cells specific to previously encountered viruses may become activated by a heterologous virus infection. Project #3 will use vaccinia virus infection as a system to examine T cell responses to a non-persistent virus only encountered once in a lifetime. Three Core Facilities will facilitate the work of these projects. The Administrative and Clinical Core will provide scientific/fiscal oversight and provide clinical samples. The Tetramer Core will provide HLA Class I/peptide tetramers for CD8 T lymphocyte assays. The Cell Science Core will provide reagents, cell separation, establishment and maintenance of cell lines. This Program will result in a deeper understanding of virus-specific T cell responses in humans, which will facilitate the development of new and improved vaccines for use in humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH
UNIVERSITY OF MASSACHUSETTS CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCE
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS
University of Massachusetts Center for Clinical and Translational Science